Browse by author
Lookup NU author(s): Professor Heinz Grunze
This work is licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0).
Background: Although a range of pharmacotherapeutical options are available for the treatment of bipolar disorder, patient non-adherence to prescribed treatment regimens and early treatment discontinuation remain among the primary obstacles to effective treatment. Therefore, this observational study assessed time on mood stabilizing medication and retention rates in patients with bipolar disorder (BD). Methods: In an 18-month, prospective, multicenter, non-interventional study conducted in Germany 761 outpatients (>= 18 years) with BD and on maintenance therapy were documented. For analysis, patients were stratified by baseline medication: monotherapy olanzapine (OM, N = 186), lithium (LM, N = 152), anticonvulsants (N = 216), other mood stabilizing medication (OMS, N = 44); combination therapy olanzapine/lithium (N = 47), olanzapine/anticonvulsant (N = 68), other combinations (OC, N = 48). Continuation on medication was assessed as retention rates with 95% confidence intervals. Time to discontinuation and relapse-free time were calculated by Kaplan-Meier analysis. A relapse was defined as increase to CGI-BP > 3, worsening of CGI-BP by >= 2 points, hospitalization or death related to BD. A Cox regression was calculated for the discontinuation of mood stabilizing therapy (reference: OM). Logistic regression models with stepwise forward selection were used to explore possible predictors of maintenance of treatment and relapse. Results: After 540 days (18 months), the overall retention rate of baseline medication was 87.7%, without notable differences between the cohorts. The overall mean time on mood stabilizing treatment was 444.7 days, with a range of 377.5 (OMS) to 481 (LM) by cohort. 74.0% of all patients were without relapse, with rates between the cohorts ranging from 58.4% (OC) to 80.2% (LM). Conclusions: Retention rates exceeded controlled trial results in all treatment cohorts, in addition to other explanations possibly reflecting that the physicians were expertly adapting treatment regimens to the individual patient's disease characteristics and special needs.
Author(s): Kraemer S, Minarzyk A, Eppendorfer S, Henneges C, Hundemer HP, Wilhelm S, Grunze H
Publication type: Article
Publication status: Published
Journal: BMC Psychiatry
Year: 2013
Volume: 13
Online publication date: 17/07/2013
Acceptance date: 07/05/2013
Date deposited: 26/11/2015
ISSN (electronic): 1471-244X
Publisher: Biomed Central Ltd.
URL: http://dx.doi.org/10.1186/1471-244X-13-193
DOI: 10.1186/1471-244X-13-193
PubMed id: 23866017
Altmetrics provided by Altmetric
